NZ772411A - Crystalline forms of c21h22ci2n4o2 - Google Patents
Crystalline forms of c21h22ci2n4o2Info
- Publication number
- NZ772411A NZ772411A NZ772411A NZ77241116A NZ772411A NZ 772411 A NZ772411 A NZ 772411A NZ 772411 A NZ772411 A NZ 772411A NZ 77241116 A NZ77241116 A NZ 77241116A NZ 772411 A NZ772411 A NZ 772411A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- crystalline form
- compound
- xrpd
- mixture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developing Agents For Electrophotography (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Removal Of Specific Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110449P | 2015-01-30 | 2015-01-30 | |
| NZ734041A NZ734041A (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22cl2n4o2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ772411A true NZ772411A (en) | 2022-05-27 |
Family
ID=56544441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ772411A NZ772411A (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
| NZ734041A NZ734041A (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22cl2n4o2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ734041A NZ734041A (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22cl2n4o2 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US9676746B2 (OSRAM) |
| EP (2) | EP3250562B1 (OSRAM) |
| JP (5) | JP7258460B2 (OSRAM) |
| CN (2) | CN116854662A (OSRAM) |
| AU (5) | AU2016211246B2 (OSRAM) |
| CA (2) | CA2975048C (OSRAM) |
| ES (1) | ES3009552T3 (OSRAM) |
| HK (1) | HK1244274A1 (OSRAM) |
| MX (1) | MX382289B (OSRAM) |
| NZ (2) | NZ772411A (OSRAM) |
| SG (2) | SG10202101979TA (OSRAM) |
| WO (1) | WO2016123574A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| EP3250562B1 (en) | 2015-01-30 | 2024-11-27 | Biomed Valley Discoveries, Inc. | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt |
| RS60747B1 (sr) * | 2016-01-27 | 2020-10-30 | Jiangsu Hengrui Medicine Co | Postupak za dobijanje farmaceutske supstance koja obuhvata derivat hinolina ili njegovu so |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| WO2021102279A1 (en) * | 2019-11-20 | 2021-05-27 | University Of Kentucky Research Foundation | Anti-cancer compositions and methods |
| WO2023169480A1 (zh) * | 2022-03-08 | 2023-09-14 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| CN119212985A (zh) * | 2022-03-24 | 2024-12-27 | 生物医学谷探索股份有限公司 | Erk的吡咯抑制剂的氘代类似物、其合成及其中间体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| WO1987002672A1 (en) | 1985-10-23 | 1987-05-07 | The Upjohn Company | Tetrahydro angiostatic steroids |
| US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| AU5640390A (en) | 1989-06-16 | 1991-01-08 | Upjohn Company, The | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| DE69232925T2 (de) | 1991-11-22 | 2003-06-18 | Alcon Laboratories, Inc. | Angiostatische steroide |
| AU782775B2 (en) * | 2000-02-05 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of ERK |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| US7354939B2 (en) * | 2004-05-14 | 2008-04-08 | Vertex Pharmaceuticals Incorporated | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| PL2091910T3 (pl) * | 2006-12-06 | 2015-02-27 | Conatus Pharmaceuticals Inc | Postacie krystaliczne kwasu (3S)-3-[N-(N’-(2-tert-butylofenylo)oksamylo)alaninylo]amino-5-(2’,3’,5’,6’-tetrafluorofenoksy)-4-oksopentanowego |
| CA2883641C (en) * | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| EP3250562B1 (en) * | 2015-01-30 | 2024-11-27 | Biomed Valley Discoveries, Inc. | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt |
-
2016
- 2016-01-29 EP EP16744240.9A patent/EP3250562B1/en active Active
- 2016-01-29 AU AU2016211246A patent/AU2016211246B2/en active Active
- 2016-01-29 MX MX2017009696A patent/MX382289B/es unknown
- 2016-01-29 CN CN202310821608.XA patent/CN116854662A/zh active Pending
- 2016-01-29 SG SG10202101979TA patent/SG10202101979TA/en unknown
- 2016-01-29 EP EP24203987.3A patent/EP4477222A3/en active Pending
- 2016-01-29 CA CA2975048A patent/CA2975048C/en active Active
- 2016-01-29 US US15/011,377 patent/US9676746B2/en active Active
- 2016-01-29 CA CA3218488A patent/CA3218488A1/en active Pending
- 2016-01-29 CN CN201680013774.5A patent/CN107406413A/zh active Pending
- 2016-01-29 NZ NZ772411A patent/NZ772411A/en unknown
- 2016-01-29 SG SG11201705924RA patent/SG11201705924RA/en unknown
- 2016-01-29 NZ NZ734041A patent/NZ734041A/en unknown
- 2016-01-29 JP JP2017539596A patent/JP7258460B2/ja active Active
- 2016-01-29 HK HK18103713.0A patent/HK1244274A1/zh unknown
- 2016-01-29 WO PCT/US2016/015829 patent/WO2016123574A1/en not_active Ceased
- 2016-01-29 ES ES16744240T patent/ES3009552T3/es active Active
-
2017
- 2017-05-17 US US15/598,181 patent/US10183927B2/en active Active
-
2018
- 2018-12-20 US US16/227,820 patent/US10738027B2/en active Active
-
2020
- 2020-03-31 JP JP2020063198A patent/JP2020100674A/ja active Pending
- 2020-07-07 US US16/922,365 patent/US11390600B2/en active Active
- 2020-10-20 AU AU2020257041A patent/AU2020257041C1/en active Active
-
2021
- 2021-12-01 JP JP2021195403A patent/JP2022033866A/ja active Pending
-
2022
- 2022-06-16 US US17/842,632 patent/US12187698B2/en active Active
- 2022-09-05 AU AU2022228084A patent/AU2022228084B2/en active Active
-
2023
- 2023-05-17 JP JP2023081553A patent/JP2023096080A/ja not_active Withdrawn
- 2023-10-25 AU AU2023254937A patent/AU2023254937B2/en active Active
-
2024
- 2024-11-26 US US18/960,604 patent/US20250084059A1/en active Pending
-
2025
- 2025-03-25 JP JP2025050047A patent/JP2025089464A/ja active Pending
- 2025-11-10 AU AU2025263912A patent/AU2025263912A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022228084B2 (en) | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | |
| JP7701758B2 (ja) | 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩 | |
| HK40119285A (en) | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt | |
| HK1247584B (en) | Crystalline c21h22c12n4o2 malonate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2024 BY CPA GLOBAL Effective date: 20221216 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241212 |